65,437 trials
Traumatic Brain Injury (TBI)
Primary: Number of Headache Days Per Week — 4.2; 4.6; 3.1; 4.3 days/week — p=<0.000
Amyotrophic Lateral Sclerosis (ALS)
Primary: Change in Revised ALS Functioning Rating Scale (ALSFRS-R) — -1; -7.1; -3.2; -7.1 Change score on ALSFRS-R
Functional Gastrointestinal Disorders
Primary: Resolution of Symptoms From Initial Rome IV Diagnosis at 3 Months Using an Age-appropriate Rome IV Questionnaire. Number of Participants Who no Longer Meet Rome IV…
Advanced Solid Tumor
Primary: Number of Participants With LY3039478 Dose-Limiting Toxicities (DLTs) — 0; 0 Participants
Teacher Training
Primary: Implementation Fidelity: Conducting Condom Line-up — 1.67; 1.26 score on an item
Metastatic Pancreatic Ductal Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v8
Primary: Disease Control Rate at 12 Weeks (DCR12) — 13; 5 Participants
Cardiac Sarcoidosis
Primary: Change in Inflammation Marker — -43; 7 mg/L
Melanoma · Non-small Cell Lung Cancer · Brain Metastasis
Primary: Brain Metastasis Response Rate (BMRR) — 54.1; 75 percentage of participants
Frailty
Primary: Frailty Index Based on Deficit Accumulation — -0.0002; 0.0002 Index score
Induced Vaginal Delivery
Primary: Time to Vaginal Delivery — 1608; 1595.5 minutes
Coronary Artery Disease (CAD)
Primary: Index of Microcirculatory Resistance (IMR) — 15; 25 mmHg·s
Colorectal Surgery
Primary: Surgical Site Infection (SSI) Rate — 16; 14; 6; 1 Participants
Cancer of the Head and Neck
Primary: Rates of Clinically Significant Radiation Dermatitis as Defined as NCI CTCAE Version 5 Grade 2 or Higher — 3; 1 Number of events
Stroke Hemorrhagic · Depression
Primary: Depression — 12.33; 6 units on a scale
Heart Failure
Primary: Number of Subjects With Adverse Drug Reactions (ADRs) — 61 Participants